Phase 1 N=82 Effects of RLIC on Motor Learning in Middle-aged and Older Adults
Adults · Older Adults
Primary: Change in Balance Score — 5.55; 4.81 seconds — p=0.984
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=180 Trial of MSC1936369B in Subjects With Solid Tumors
Solid Tumors · Cancer
Primary: Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21 — 2; 6; 0; 6 Subjects
Phase 1 N=24 A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
Major Depressive Disorder
Primary: Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 1 — 13.3; 3.6; 57.5; 33.1 beats per minute (bpm) — p=<0.0001
Phase 1 N=32 A Study for Japanese Participants With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events (AEs) [Clinically Significant Effects] — 0; 1; 1; 1 Participants
Phase 1 N=20 A Study of LY2216684 in Healthy Females
Depressive Disorder, Major
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norelgestromin — 79.0; 80.9; 1438; 1574 picograms/milliliter (pg/mL)
Phase 1 N=48 A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
Major Depressive Disorder
Primary: Maximum, Minimum and Average Changes in Heart Rate — 33.4; 15.7; 35.7; 31.1 beats per minute (bpm)
Phase 1 N=9 A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Advanced Solid Tumors
Primary: Number of Participants With Adverse Events (AEs) or Deaths — 2; 3; 2; 0 Participants
Phase 1 N=30 A Study of LY2216684 and Digoxin in Healthy Subjects
Major Depressive Disorder
Primary: Pharmacokinetics of Digoxin: Maximum Plasma Concentration (Cmax) — 1.433; 1.424 nanograms/milliliter (ng/mL)
Phase 1 N=47 A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
Major Depressive Disorder
Primary: Pharmacokinetics of R-130964, Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) — 61.8; 55.3 hours*nanograms/milliliters (h*ng/mL)
Phase 1 N=36 A Study of LY2216684 in Participants With Impaired Hepatic Function
Depressive Disorder, Major
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) — 601; 742; 961; 1020 hours times nanograms/milliliter
Phase 1 N=20 A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
Major Depressive Disorder
Primary: Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684 — 677; 1210 hour*nanogram per…
Phase 1 N=75 A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
Healthy
Primary: Drug Liking: Peak Effect (Emax) — 51.6; 70.1; 85.5; 59.3 mm — p=<0.0001
Phase 1 N=31 Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
Cancer
Primary: Number of Participants With Adverse Events (AEs) — 3; 3; 3; 13 Participants
Phase 1 N=18 A Study of LY2605541 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541 — 128000; 145000; 135000 picomoles times hours per liter
Phase 1 N=14 A Study to Evaluate the Effect of Clarithromycin on LY2216684
Depressive Disorder, Major
Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684 — 582; 746 nanogram*hours per milliliter (ng*h/mL)